Cibelly Goulart

Cibelly Goulart

Auto-generated profile, based on publicly available information

Cibelly Goulart

Centro de Biotecnologia, Instituto Butantan, São Paulo, Brazil

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 July 2013 in Critical Reviews in Microbiology
Verified
Journal Article
Closed access
MDMichelle Darrieux
Michelle Darrieux
CGCibelly Goulart
Cibelly Goulart
DBDavid Briles
David Briles
LLLuciana C. C. Leite
Luciana C. C. Leite
Despite the efforts to expand the availability of conjugate vaccines, pneumococcal diseases still pose an enormous burden worldwide. Therefore, several proteins have been investigated as alternative vaccines, alone or in combination with other antigens. With an increasing array of techniques, many of which arose from the publication of the bacterial genome, several proteins have been identified as potential vaccine candidates, and some have even progressed to clinical trials. Also, whole cell vaccines are being studied for the induction of broad ranging protective responses. Here, we briefly summarize the current knowledge on pneumococcal proteins that are being investigated as potential vaccine candidates against pneumococcal infections, and provide an insight on the future generation of protein-based vaccines against Streptococcus pneumoniae.

7 November 2018 in mBio
Verified
Journal Article
Open access
PDF file
FZFan Zhang
Fan Zhang
OLOlivia Ledue
Olivia Ledue
MJMaria Jun
Maria Jun
CGCibelly Goulart
Cibelly Goulart
RMRichard Malley
Richard Malley
YLYing-Jie Lu
Ying-Jie Lu
S. aureusis a leading cause of healthcare- and community-associated bacterial infections.S. aureuscauses various illnesses, including bacteremia, meningitis, endocarditis, pneumonia, osteomyelitis, sepsis, and skin and soft tissue infections.S. aureuscolonizes between 20 and 80% of humans; carriers are at increased risk for infection and transmission to others. The spread of multidrug-resistant strains limits antibiotic treatment options. Vaccine development againstS. aureushas been unsuccessful to date, likely due to an inadequate understanding about the mechanisms of immune defense against this pathogen. The significance of our work is in illustrating the necessity of generating multipronged B-cell, Th1-, and Th17-mediated responses toS. aureusantigens in conferring enhanced and broad protection againstS. aureusinvasive infection, skin and soft tissue infection, and mucosal colonization. Our work thus, provides important insights for future vaccine development against this pathogen.

1 February 2011 in Vaccine
Verified
Journal Article
Closed access
CGCibelly Goulart
Cibelly Goulart
MDMichelle Darrieux
Michelle Darrieux
DSDunia Del Carmen Rodriguez Soto
Dunia Del Carmen Rodriguez Soto
FPFabiana C. Pimenta
Fabiana C. Pimenta
MBMaria Cristina C. Brandileone
Maria Cristina C. Brandileone
LLLuciana C. C. Leite
Luciana C. C. Leite

22 March 2013 in PLOS ONE
Verified
Journal Article
Open access
PDF file
CGCibelly Goulart
Cibelly Goulart
TSThais Raquel da Silva
Thais Raquel da Silva
DSDunia Del Carmen Rodriguez Soto
Dunia Del Carmen Rodriguez Soto
WPWalter Rodrigo Politano
Walter Rodrigo Politano
LLLuciana C. C. Leite
Luciana C. C. Leite
MDMichelle Darrieux
Michelle Darrieux
Pneumococcal surface protein A (PspA) and Pneumolysin derivatives (Pds) are important vaccine candidates, which can confer protection in different models of pneumococcal infection. Furthermore, the combination of these two proteins was able to increase protection against pneumococcal sepsis in mice. The present study investigated the potential of hybrid proteins generated by genetic fusion of PspA fragments to Pds to increase cross-protection against fatal pneumococcal infection. Pneumolisoids were fused to the N-terminus of clade 1 or clade 2 pspA gene fragments. Mouse immunization with the fusion proteins induced high levels of antibodies against PspA and Pds, able to bind to intact pneumococci expressing a homologous PspA with the same intensity as antibodies to rPspA alone or the co-administered proteins. However, when antibody binding to pneumococci with heterologous PspAs was examined, antisera to the PspA-Pds fusion molecules showed stronger antibody binding and C3 deposition than antisera to co-administered proteins. In agreement with these results, antisera against the hybrid proteins were more effective in promoting the phagocytosis of bacteria bearing heterologous PspAs in vitro, leading to a significant reduction in the number of bacteria when compared to co-administered proteins. The respective antisera were also capable of neutralizing the lytic activity of Pneumolysin on sheep red blood cells. Finally, mice immunized with fusion proteins were protected against fatal challenge with pneumococcal strains expressing heterologous PspAs. Taken together, the results suggest that PspA-Pd fusion proteins comprise a promising vaccine strategy, able to increase the immune response mediated by cross-reactive antibodies and complement deposition to heterologous strains, and to confer protection against fatal challenge.

1 July 2014 in Vaccine
Verified
Journal Article
Closed access
KAKarine M. De Amicis
Karine M. De Amicis
SBSamar Freschi de Barros
Samar Freschi de Barros
RARaquel E. Alencar
Raquel E. Alencar
EPEdilberto Postól
Edilberto Postól
CMCarlo de Oliveira Martins
Carlo de Oliveira Martins
LGLuiza Guilherme
Luiza Guilherme

1 June 2013 in Clinical and Vaccine Immunology
Verified
Journal Article
Open access
PDF file
CPCatia T. Perciani
Catia T. Perciani
GBGiovana Barazzone
Giovana Barazzone
CGCibelly Goulart
Cibelly Goulart
ECEneas Carvalho
Eneas Carvalho
JCJoaquin Cabrera-Crespo
Joaquin Cabrera-Crespo
MTMartha M. Tanizaki
Martha M. Tanizaki
Despite the substantial beneficial effects of incorporating the 7-valent pneumococcal conjugate vaccine (PCV7) into immunization programs, serotype replacement has been observed after its widespread use. As there are many serotypes currently documented, the use of a conjugate vaccine relying on protective pneumococcal proteins as active carriers is a promising alternative to expand PCV coverage. In this study, capsular polysaccharide serotype 6B (PS6B) and recombinant pneumococcal surface protein A (rPspA), a well-known protective antigen fromStreptococcus pneumoniae, were covalently attached by two conjugation methods. The conjugation methodology developed by our laboratory, employing 4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholinium chloride (DMT-MM) as an activating agent through carboxamide formation, was compared with reductive amination, a classical methodology. DMT-MM-mediated conjugation was shown to be more efficient in coupling PS6B to rPspA clade 1 (rPspA1): 55.0% of PS6B was in the conjugate fraction, whereas 24% was observed in the conjugate fraction with reductive amination. The influence of the conjugation process on the rPspA1 structure was assessed by circular dichroism. According to our results, both conjugation processes reduced the alpha-helical content of rPspA; reduction was more pronounced when the reaction between the polysaccharide capsule and rPspA1 was promoted between the carboxyl groups than the amine groups (46% and 13%, respectively). Regarding the immune response, both conjugates induced functional anti-rPspA1 and anti-PS6B antibodies. These results suggest that the secondary structure of PspA1, as well as its reactive groups (amine or carboxyl) involved in the linkage to PS6B, may not play an important role in eliciting a protective immune response to the antigens.